Natural psychedelics drug developer Filament Health Corp. (OTCQB: FLHLF) shared its interim financial results and further business highlights for the first quarter ended March 31, 2023.

These results were assembled by the company’s management and were not reviewed by the independent auditor as of May 12 and reportedly “do not include all the information and notes required by International Financial Reporting Standards (IFRS) for annual financial statements.”

Further, the filing’s Note 1 describes “the material uncertainty that may cast significant doubt on the company’s ability to continue as an ongoing concern.

See also: Filament Health: 2022 Financials And Operational Highlights From Creator Of The Ayahuasca Pill

Numbers for the quarter ended March 31, including …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.